EUVIMEDEUVIMED entdecken
Crossref

mTOR ‐mediated upregulation of B7 ‐ H3 in MiT / TFE translocation renal cell carcinoma

Huili Li, Adrianna Amaral, Thiago Vidotto, Juhyung Woo, Hans B Liu, Lia D Oliveira, Oluwademilade Dairo, Kewen Feng, Eugene Shenderov, Pedram Argani, Laura S Schmidt, W Marston Linehan und 2 weitere

The Journal of Pathology · 2026

DOI: 10.1002/path.6490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2026. Verfasst von Huili Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, B7 Antigens, TOR Serine-Threonine Kinases, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Congressionally Directed Medical Research Programs, NCI NIH HHS, Dahan Translocation Carcinoma Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials targeting B7‐H3 ( CD276 ), a membranous immunomodulatory molecule in the B7 superfamily, have shown promise in prostate cancer and may be expanded to additional tumor types with high expression, such as those with mTOR signaling activation. MiT/TFE‐rearranged translocation renal cell carcinoma (tRCC) is a rare, aggressive subtype that is relatively immune‐depleted, with high levels of mTOR activity. Thus, we assessed B7‐H3 expression in preclinical tRCC models and human tRCC samples. As hypothesized, we found that induction of TFE3 fusion proteins, including SFPQ‐TFE3, PRCC‐TFE3, ASPSCR1‐TFE3, and NONO‐TFE3, is associated with upregulation of B7‐H3 in multiple human preclinical tRCC cell line systems and transgenic mouse models. Pharmacologic or genetic inhibition of mTOR signaling is sufficient to downregulate B7‐H3 expression in inducible and patient‐derived, human cell line models of tRCC. In keeping with these preclinical results, human tRCC demonstrated significantly higher gene expression of CD276 than normal kidney, across five of the six fusions studied. At the protein level, tRCC had higher tumor cell B7‐H3 intensity and proportion scores than normal kidney or clear cell RCC (ccRCC). B7‐H3 expression in tumor vasculature was similar in tRCC and ccRCC, both of which showed significantly higher expression than normal kidney. Within tRCC cases, higher CD276 expression was observed in metastatic compared to localized tumors and was associated with lower tumoral CD4 + T‐cell content by bulk RNAseq deconvolution. Taken together, tRCC fusion proteins upregulate B7‐H3 expression via increased mTOR signaling, resulting in a higher tumoral B7‐H3 expression compared to normal kidney or conventional RCC, suggesting that B7‐H3 may be a promising therapeutic target in tRCC. © 2025 The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellB7 AntigensTOR Serine-Threonine KinasesKidney NeoplasmsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsTranslocation, GeneticHumansAnimalsUp-RegulationSignal TransductionCell Line, TumorGene Expression Regulation, NeoplasticMiceMice, TransgenicMaleOncogene Proteins, Fusion

Stichwörter der Autor:innen

B7‐H3GPNMBTFE3TFEBmTORrenal cell carcinomatranslocation renal cell carcinoma (tRCC)

Substanzen

B7 AntigensTOR Serine-Threonine KinasesCD276 protein, humanMTOR protein, humanTFE3 protein, humanBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Department of Urology and Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

ORCID-Profile: Tamara L Lotan, Kaushal Asrani

Förderung

  • Congressionally Directed Medical Research Programs
  • NCI NIH HHS
  • Dahan Translocation Carcinoma Fund
  • Joey's Wings Foundation
  • Office of Intramural Training and Education
  • Center for Cancer Research (WML)
  • NIH HHS
  • National Cancer Institute

Zitieren

APA

Li, H., Amaral, A., Vidotto, T., Woo, J., Liu, H. B., Oliveira, L. D., Dairo, O., Feng, K., Shenderov, E., Argani, P., Schmidt, L. S., Linehan, W. M., Lotan, T. L., & Asrani, K. (2026). mTOR ‐mediated upregulation of B7 ‐ H3 in MiT / TFE translocation renal cell carcinoma. The Journal of Pathology. https://doi.org/10.1002/path.6490

Vancouver

Li H, Amaral A, Vidotto T, Woo J, Liu HB, Oliveira LD, et al. mTOR ‐mediated upregulation of B7 ‐ H3 in MiT / TFE translocation renal cell carcinoma. The Journal of Pathology. 2026. doi:10.1002/path.6490

BibTeX
@article{Li2026,
  author = {Li, Huili and Amaral, Adrianna and Vidotto, Thiago and Woo, Juhyung and Liu, Hans B and Oliveira, Lia D and Dairo, Oluwademilade and Feng, Kewen and Shenderov, Eugene and Argani, Pedram and Schmidt, Laura S and Linehan, W Marston and Lotan, Tamara L and Asrani, Kaushal},
  title = {mTOR ‐mediated upregulation of B7 ‐ H3 in MiT / TFE translocation renal cell carcinoma},
  journal = {The Journal of Pathology},
  year = {2026},
  doi = {10.1002/path.6490}
}
Kostenlos starten →